The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer’s Disease: The Okayama Depression and Apathy Project (ODAP)

Japanese Old Stories Cognitive Scale: a screening test to detect cognitive disease and prompt visiting a memory clinic

(2019) Yasuyuki Honjo et al.   Psychogeriatrics

Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial

(2019) Stephan Ehrhardt et al.   Alzheimers & Dementia

Why Do They Just Sit? Apathy as a Core Symptom of Alzheimer Disease

(2018) Carolyn W. Zhu et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

Therapeutic effects of drug switching between acetylcholinesterase inhibitors in patients with Alzheimer's disease

(2017) Yasuyuki Ohta et al.   Geriatrics & Gerontology International

Characteristic features of cognitive, affective and daily living functions of late-elderly dementia

(2015) Nozomi Hishikawa et al.   Geriatrics & Gerontology International

Comparison of Sertraline, Venlafaxine and Desipramine Effects on Depression, Cognition and the Daily Living Activities in Alzheimer Patients

(2014) N. Mokhber et al.   PHARMACOPSYCHIATRY

Efficacy of sertraline in a patient with Neuro-Beçhet’s disease

(2013) G. Tosto et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Sertraline for the Treatment of Depression in Alzheimer Disease: Week-24 Outcomes

(2010) Daniel Weintraub et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats

(2010) Yuji Kitaichi et al.   EUROPEAN JOURNAL OF PHARMACOLOGY